Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juliannie Herrera
Observed name:
Herrera, Juliannie
Institutions:
Medical College of Wisconsin,
Medical College of Wisconsin Cancer Center
Observed institutions:
Medical College of Wisconsin,
Medical College of Wisconsin Cancer Center
ORCID:
0009-0008-2034-9695
Observed ORCID:
0009-0008-2034-9695
OpenAlex ID:
A5135741205
Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
·
Cancer Research
·
4
PDF
Figure S2 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Figure S4 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Figure S1 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Data from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Figure S6 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Figure S3 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Figure S5 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
Supplementary Figure 4 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Table 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 4 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Data from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Table 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.
2026
·
Der, Channing J
, Thalji, Sam Z
, et al.
·
UNC Libraries
Show more works
View as search
Works count:
22
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type